PDK4 and TBX3 enable further classification of ER+ breast cancers
(A) Immunohistochemistry of breast TMA for PDK4 and TBX3.
(B) ER+ breast cancers expressing lower levels of PDK4 compared to tumors with higher PDK4 and not received endocrine therapy were associated with poor disease-free survival (DFS). Similarly, ER+ tumors expressing lower levels of both TBX3 and PDK4 compared to tumors expressing higher levels of PDK4 and TBX3 were associated with poor DFS.